Key result
Maternal plasma NTproCNP levels in late pregnancy were increased in women with pre-eclampsia and gestational hypertension with small for gestational age compared to controls.
Why the study?
Does plasma NTproCNP change in pregnancies complicated by pre-eclampsia or gestational hypertension with small for gestational age compared to uncomplicated pregnancies?
Case-Control (n=60)
No
Does plasma NTproCNP change in pregnancies complicated by pre-eclampsia or gestational hypertension with small for gestational age compared to uncomplicated pregnancies?
Maternal plasma NTproCNP is significantly elevated in late pregnancy in women with pre-eclampsia and gestational hypertension with fetal growth restriction, correlating with concurrent blood pressure.
Answers are grounded in this paper and cite their sources.
NTproCNP elevation is associated with pre-eclampsia and SGA-complicated hypertension; hypothesis-generating and should not yet change practice.
OBJECTIVE: To determine changes in plasma C-type natriuretic peptide (CNP), a paracrine product of the vascular endothelium, in pregnancies with vascular disorders, and relate these to time of presentation and severity. DESIGN: Retrospective nested cases and controls. SETTING: Community study, Auckland New Zealand. POPULATION: Screening for Pregnancy Endpoints (SCOPE) data and bio-bank of maternal plasma. METHODS: Maternal plasma amino terminal proCNP (NTproCNP) was measured by radioimmunoassay in early (14-16 weeks of gestation, and again at 19-21 weeks of gestation) and late (34-36 weeks of gestation) pregnancy in three groups of women (20 per group): pre-eclampsia (pre-eclampsia); gestational hypertension (GHT) with small for gestational age (SGA); and uncomplicated pregnancy. MAIN OUTCOME MEASURES: Change in NTproCNP and associations with concurrent blood pressure, time of case presentation, severity, and infant birthweight. RESULTS: Plasma NTproCNP in early pregnancy in women with vascular disorders did not differ from those found in controls. In late pregnancy, levels in pre-eclampsia (28.8 ± 2.3 pM) and in GHT with SGA (28.6 ± 4.8 pM) were significantly increased (P = 0.01 and 0.027, respectively) compared with controls (21.3 ± 1 pM). In pre-eclampsia, levels were significantly higher (P < 0.03) at 14-16 weeks of gestation in women diagnosed prior to 34 weeks of gestation. Combining all three groups, associations of NTproCNP with concurrent diastolic and mean arterial pressure were found at 34-36 weeks of gestation (r = 0.46). No significant associations were identified with birthweight. CONCLUSIONS: CNP secretion during gestation is responsive to vascular stress. Plasma NTproCNP measurements may have clinical application in late pregnancy in defining the different phenotypes associated with pre-eclampsia.
No takes yet. Share an insight, caveat, or question.
Espiner et al. (2015) conducted a case-control in Pre-eclampsia and fetal growth restriction (n=60). Pre-eclampsia and gestational hypertension with small for gestational age vs. Uncomplicated pregnancy was evaluated on Plasma NTproCNP concentration in late pregnancy (34-36 weeks of gestation) in pre-eclampsia (p=0.01). Maternal plasma NTproCNP levels in late pregnancy were increased in women with pre-eclampsia and gestational hypertension with small for gestational age compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: